Syngene Targets Brain Biomarker to Boost Anxiety Drug Research

Key Highlights:-

• Syngene emphasizes precise brain biomarker measurement for mood and anxiety drug development
• 2-AG, linked to the endocannabinoid system, is a promising target for treating anxiety and depression
• The bioanalytical approach supports pharmaceutical innovation with reliable biomarker data in early drug discovery

In the developing side of drug development for mood and anxiety disorders, Syngene has stressed the critical need to precisely measure brain biomarkers to better understand disease pathways and assess drug efficacy.

The success of this advancement is Syngene’s Drug Metabolism and Pharmacokinetics (DMPK) team, which has engineered a highly sensitive LC-MS/MS method to calculate the biomarker 2-Arachidonoylglycerol (2-AG) in mouse brain tissue. This biomarker is closely protected to the endocannabinoid (eCB) system at a regulator of emotional and neurological responses which making it a promising candidate in treating emotional disorders such as anxiety and depression.

Scientific evidence suggests that a deficiency in 2-AG may play a role in the development of these conditions. Syngene’s research indicates that restoring 2-AG balance could provide a powerful therapeutic approach. In a recent study, CD1 mice subjected to stress and then treated with the MAGL inhibitor JZL184 (10 mg/kg, administered intraperitoneally) showed a important two-fold increase in brain 2-AG levels. More importantly, the treatment also reversed behavioral symptoms of anxiety and depression in the mice, endorsing the potential of targeting the 2-AG pathway.

Also read: Gujarat Set to Approve Surat Drug Lab, Says FDCA Chief

Unlike conservative bioanalytical strategies, Syngene’s method overcomes the challenge of measuring 2-AG, which naturally exists even in unprocessed samples. Their customized LC-MS/MS platform was meticulously improved for enhanced sensitivity and precision, ensuring exact detection of even delicate changes in biomarker levels.

Internal studies further confirmed these results, revealing up to a five-fold increase in 2-AG in treated mice compared to the control group. These findings not only demonstrate the efficacy of JZL184 but also offer a reliable method for measuring 2-AG making a way to deeper exploration into the eCB system’s therapeutic potential.

Syngene highlighted that this personalized bioanalytical method represents a major step forward in preclinical neuroscience research. It allows pharmaceutical developers to make informed decisions based on strong and reproducible biomarker data. Syngene offers advanced, fit-for-purpose bioanalytical solutions customized to early-stage drug discovery, supporting both small molecule and biologics development. Their DMPK capabilities are designed to unlock insights that accelerate innovation in precision medicine and biomarker-driven drug schemes.